{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:26:43Z","timestamp":1789075603331,"version":"build-2803163510"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,24]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Most cancer patients suffer from the pain of chemotherapy-induced nausea and vomiting (CINV). This meta-analysis was performed to evaluate the efficacy and safety of a regimen consisting of aprepitant, dexamethasone, and 5-HT3 receptor antagonists in the prevention and treatment of CINV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic literature search was conducted across multiple databases, including PubMed, EMbase, Cochrane Library, MEDLINE, CENTRAL, HEED, CNKI, Wanfang, and VIP, to identify randomized controlled trials (RCTs) investigating the use of triple therapy (aprepitant, 5-HT<jats:sub>3<\/jats:sub> receptor antagonist, and dexamethasone) to prevent and treat CINV. Meta-analysis was performed using RevMan 5.4 and Stata17 software, employing either a fixed-effect or random-effect model based on statistical heterogeneity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A meta-analysis of 23 randomized controlled trials (RCTs) involving 7956 patients was conducted. Efficacy: Results showed significantly improved complete responses (CRs) for CINV in the test group versus the control group in the overall, acute, and delayed phases. Furthermore, in the test group, substantial alleviation of nausea symptoms was observed in the delayed and overall phases but not in the acute phase. Safety: There was no statistically significant difference in the incidence of febrile neutropenia, diarrhea, anorexia, and headache between the 2 groups. The incidence of fatigue and hiccups in the test group was higher than that in the control group; however, the incidence of constipation was significantly lower.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Aprepitant-containing triple therapy is highly effective in the prevention and treatment of CINV, with reliable medication safety.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035952","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T19:03:31Z","timestamp":1701716611000},"page":"e35952","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis"],"prefix":"10.1097","volume":"102","author":[{"given":"Min","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Weifang People\u2019s Hospital, Weifang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Li","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Weifang People\u2019s Hospital, Weifang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Weifang People\u2019s Hospital, Weifang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Weifang People\u2019s Hospital, Weifang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Tai","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Weifang People\u2019s Hospital, Weifang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Yao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Weifang People\u2019s Hospital, Weifang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Li","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Weifang People\u2019s Hospital, Weifang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250524","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250524","first-page":"1","article-title":"Cancer incidence and mortality in China, 2016.","volume":"2","author":"Zheng","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"R3-20250524","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants.","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"R4-20250524","first-page":"875","article-title":"Relationship between nutritional status and chemotherapy incduced adverse reactions and cancer related fatigue in patients with lung cancer (\u80ba\u764c\u60a3\u8005\u8425\u517b\u72b6\u6001\u4e0e\u5316\u7597\u4e0d\u826f\u53cd\u5e94\u53ca\u764c\u56e0\u6027\u75b2\u4e4f\u7684\u76f8\u5173\u6027\u7814\u7a76).","volume":"29","author":"Chen","year":"2022","journal-title":"Chin J Clin Oncol Rehabil"},{"key":"R5-20250524","first-page":"6827","article-title":"Relationship Between the Nutritional Status and the Treatment Tolerance, Efficacy and Adverse Reactions of Chemotherapy in Patients with Advanced Colorectal Cancer (\u665a\u671f\u7ed3\u76f4\u80a0\u764c\u5316\u7597\u60a3\u8005\u8425\u517b\u72b6\u51b5\u4e0e\u6cbb\u7597\u8010\u53d7\u6027\u3001\u7597\u6548\u53ca\u5316\u7597\u4e0d\u826f\u53cd\u5e94\u7684\u5173\u7cfb).","volume":"30","author":"Zhang","year":"2021","journal-title":"Henan Med Res"},{"key":"R6-20250524","first-page":"61","article-title":"Observation on the effect of nutritional status of patients undergoing chemotherapy for gastrointestinal tumors on adverse reactions of chemotherapy (\u80c3\u80a0\u80bf\u7624\u672f\u540e\u5316\u7597\u60a3\u8005\u7684\u8425\u517b\u72b6\u51b5\u5bf9\u5316\u7597\u4e0d\u826f\u53cd\u5e94\u7684\u5f71\u54cd\u89c2\u5bdf).","volume":"12","author":"Zhuang","year":"2021","journal-title":"China Health Standard Manage"},{"key":"R7-20250524","doi-asserted-by":"crossref","first-page":"257","DOI":"10.31083\/j.ejgo4302032","article-title":"Relationship between nutritional status and health-related quality of life in patients receiving chemotherapy after radical ovarian cancer surgery: a cross-sectional study.","volume":"43","author":"Qin","year":"2022","journal-title":"Eur J Gynecol Oncol"},{"key":"R8-20250524","doi-asserted-by":"crossref","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends.","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"R9-20250524","first-page":"1228","article-title":"Research progress of combined application of antiemetic drugs in chemotherapy (\u5316\u7597\u6b62\u5410\u836f\u7269\u8054\u5408\u5e94\u7528\u7684\u7814\u7a76\u8fdb\u5c55).","volume":"25","author":"Li","year":"2019","journal-title":"Med Recapitul"},{"key":"R10-20250524","first-page":"1262","article-title":"New Advances in Chemotherapy-induced Nausea and Vomiting (\u5316\u7597\u81f4\u6076\u5fc3\u5455\u5410\u7684\u7814\u7a76\u8fdb\u5c55).","volume":"21","author":"Zhou","year":"2018","journal-title":"China Pharmacist"},{"key":"R11-20250524","first-page":"1361","article-title":"Risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy.","volume":"29","author":"Eliasen","year":"2022","journal-title":"J Oncol Pract"},{"key":"R12-20250524","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1158\/1078-0432.CCR-21-1941","article-title":"Developing drugs for prevention of chemotherapy-induced nausea and vomiting: draft guidance from the FDA.","volume":"27","author":"Lyons","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R13-20250524","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","article-title":"Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.","volume":"26","author":"Aogi","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"R14-20250524","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","article-title":"ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients.","volume":"27","author":"Razvi","year":"2019","journal-title":"Support Care Cancer"},{"key":"R15-20250524","doi-asserted-by":"crossref","first-page":"e1073","DOI":"10.1002\/onco.13716","article-title":"Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data.","volume":"26","author":"Aapro","year":"2021","journal-title":"Oncologist"},{"key":"R16-20250524","doi-asserted-by":"crossref","first-page":"660514","DOI":"10.3389\/fpubh.2021.660514","article-title":"Cost-effectiveness of aprepitant in preventing chemotherapy-induced nausea and vomiting: a systematic review of published articles.","volume":"9","author":"Qiu","year":"2021","journal-title":"Front Public Health"},{"key":"R17-20250524","first-page":"60","article-title":"Emetogenicity of chemotherapy regimens and recommended prophylaxis: a review of MASCC\/ESMO guidelines.","volume":"7","author":"Celio","year":"2022","journal-title":"EMJ"},{"key":"R18-20250524","first-page":"3080","article-title":"Consensus of experts on the prevention and treatment of nausea and vomiting related to cancer drug therapy in China (2022) [\u4e2d\u56fd\u80bf\u7624\u836f\u7269\u6cbb\u7597\u76f8\u5173\u6076\u5fc3\u5455\u5410\u9632\u6cbb\u4e13\u5bb6\u5171\u8bc6\uff082022\u5e74\u7248\uff09].","volume":"102","author":"Feng","year":"2022","journal-title":"Natl Med J China"},{"key":"R19-20250524","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00520-016-3371-3","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer.","volume":"25","author":"Walsh","year":"2017","journal-title":"Support Care Cancer"},{"key":"R20-20250524","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update.","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"R21-20250524","first-page":"1964","article-title":"Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: a retrospective analysis from a large academic medical center.","volume":"26","author":"Gamble","year":"2020","journal-title":"J Oncol Pract"},{"key":"R22-20250524","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2022.01.028","article-title":"Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: results of the nausea\/emesis registry in oncology (NERO).","volume":"166","author":"Aapro","year":"2022","journal-title":"Eur J Cancer"},{"key":"R23-20250524","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40266-021-00909-8","article-title":"Prevention of chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes.","volume":"39","author":"Herrstedt","year":"2022","journal-title":"Drugs Aging"},{"key":"R24-20250524","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R25-20250524","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1007\/s00520-015-2714-9","article-title":"Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.","volume":"23","author":"Bakhshi","year":"2015","journal-title":"Support Care Cancer"},{"key":"R26-20250524","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41409-018-0106-8","article-title":"A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT).","volume":"53","author":"Bubalo","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R27-20250524","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.11320","article-title":"Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.","volume":"97","author":"Chawla","year":"2003","journal-title":"Cancer"},{"key":"R28-20250524","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pbc.21811","article-title":"Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.","volume":"52","author":"Gore","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R29-20250524","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/cncr.21222","article-title":"Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.","volume":"104","author":"Gralla","year":"2005","journal-title":"Cancer"},{"key":"R30-20250524","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/cncr.21343","article-title":"Aprepitant Moderately Emetogenic Chemotherapy Study Group Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.","volume":"104","author":"Herrstedt","year":"2005","journal-title":"Cancer"},{"key":"R31-20250524","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.","volume":"23","author":"Warr","year":"2005","journal-title":"J Clin Oncol"},{"key":"R32-20250524","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.","volume":"19","author":"Warr","year":"2011","journal-title":"Support Care Cancer"},{"key":"R33-20250524","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","article-title":"The Oral Neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin \u2013 The Aprepitant Protocol 052 Study Group.","volume":"21","author":"Hesketh","year":"2003","journal-title":"J Clin Oncol"},{"key":"R34-20250524","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00520-013-2043-9","article-title":"Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.","volume":"22","author":"Hu","year":"2014","journal-title":"Support Care Cancer"},{"key":"R35-20250524","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.","volume":"16","author":"Kang","year":"2015","journal-title":"Lancet Oncol"},{"key":"R36-20250524","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00520-016-3463-0","article-title":"Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.","volume":"25","author":"Kim","year":"2017","journal-title":"Support Care Cancer"},{"key":"R37-20250524","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy\u2010induced nausea and vomiting: Results from a randomized, double\u2010blind, placebo\u2010controlled trial in Latin America.","volume":"97","author":"Poli-Bigelli","year":"2003","journal-title":"Cancer"},{"key":"R38-20250524","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.","volume":"18","author":"Rapoport","year":"2010","journal-title":"Support Care Cancer"},{"key":"R39-20250524","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1185\/03007995.2014.925866","article-title":"Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.","volume":"30","author":"Rapoport","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"R40-20250524","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","article-title":"Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.","volume":"32","author":"Schmitt","year":"2014","journal-title":"J Clin Oncol"},{"key":"R41-20250524","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","article-title":"Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.","volume":"17","author":"Schmoll","year":"2006","journal-title":"Ann Oncol"},{"key":"R42-20250524","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbmt.2012.07.019","article-title":"Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.","volume":"19","author":"Stiff","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R43-20250524","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000371523","article-title":"Addition of Aprepitant (Emend\u00ae) to standard antiemetic regimen continued for 7 days after chemotherapy for stem cell transplantation provides significant reduction of vomiting.","volume":"89","author":"Svanberg","year":"2015","journal-title":"Oncology (Huntingt)"},{"key":"R44-20250524","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1111\/j.1349-7006.2010.01689.x","article-title":"Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin.","volume":"101","author":"Takahashi","year":"2010","journal-title":"Cancer Sci"},{"key":"R45-20250524","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bjc.2013.400","article-title":"A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.","volume":"109","author":"Tanioka","year":"2013","journal-title":"Br J Cancer"},{"key":"R46-20250524","doi-asserted-by":"crossref","first-page":"e215250","DOI":"10.1001\/jamanetworkopen.2021.5250","article-title":"Effect of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial.","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R47-20250524","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ejca.2005.01.024","article-title":"The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.","volume":"41","author":"Warr","year":"2005","journal-title":"Eur J Cancer"},{"key":"R48-20250524","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/j.cllc.2018.08.006","article-title":"Phase III randomized trial of palonosetron and dexamethasone with or without aprepitant to prevent nausea and vomiting induced by full-dose single-day cisplatin-based chemotherapy in lung cancer.","volume":"19","author":"Wu","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R49-20250524","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","article-title":"Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.","volume":"21","author":"Yahata","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"R50-20250524","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-008-9957-9","article-title":"A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.","volume":"113","author":"Yeo","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"R51-20250524","first-page":"32","article-title":"Advances in the prevention and treatment of chemotherapy \u2013 induced nausea and vomiting (\u80bf\u7624\u5316\u7597\u76f8\u5173\u6027\u6076\u5fc3\u5455\u5410\u7684\u9632\u6cbb\u8fdb\u5c55).","volume":"26","author":"Yang","year":"2019","journal-title":"China Mod Med"},{"key":"R52-20250524","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3390\/cancers12092682","article-title":"The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer?","volume":"12","author":"Mu\u00f1oz","year":"2020","journal-title":"Cancers"},{"key":"R53-20250524","doi-asserted-by":"crossref","first-page":"100462","DOI":"10.1016\/j.currproblcancer.2019.01.003","article-title":"Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting.","volume":"43","author":"Li","year":"2019","journal-title":"Curr Probl Cancer"},{"key":"R54-20250524","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2019.09.021","article-title":"Multiple uses of forest plots in presenting analysis results in health research: a Tutorial.","volume":"117","author":"Li","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"R55-20250524","first-page":"314","article-title":"How do clinicians undersand meta-analysis (\u4e34\u5e8a\u533b\u751f\u5982\u4f55\u89e3\u8bfbMeta\u5206\u6790\u8bba\u6587).","volume":"11","author":"Zhu","year":"2020","journal-title":"Med J Pumch"},{"key":"R56-20250524","first-page":"3255","article-title":"Meta-analysis of aprepitant combined with 5-HT3RA in the prevention of chemotherapy induced vomiting (\u963f\u745e\u5339\u5766\u8054\u54085-HT3RA\u9884\u9632\u5316\u7597\u5f15\u8d77\u5455\u5410\u7684 Meta\u5206\u6790).","volume":"32","author":"Yang","year":"2016","journal-title":"J Pract Med"},{"key":"R57-20250524","doi-asserted-by":"crossref","first-page":"e21559","DOI":"10.1097\/MD.0000000000021559","article-title":"Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: an updated systematic review and meta-analysis.","volume":"99","author":"Qiu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R58-20250524","first-page":"3269","article-title":"Efficacy and safety of NK-1 receptor inhibitor combined with dexamethasone and 5- HT3 receptor inhibitor for the prevention and treatment of carboplatin- based chemotherapy-induced nausea and vomiting: a meta-analysis (NK-1\u53d7\u4f53\u6291\u5236\u5242\u8054\u5408\u5730\u585e\u7c73\u677e\u4e0e5-HT3\u53d7\u4f53\u6291\u5236\u5242\u9884\u9632\u548c\u6cbb\u7597\u4ee5\u5361\u94c2\u4e3a\u57fa\u7840\u7684\u5316\u7597\u5bfc\u81f4\u7684\u6076\u5fc3\u5455\u5410\u7684\u7597\u6548\u4e0e\u5b89\u5168\u6027\u7684Meta\u5206\u6790).","volume":"29","author":"Liu","year":"2018","journal-title":"China Pharm"},{"key":"R59-20250524","first-page":"2559","article-title":"Meta-analysis of aprepitant in the prevention of nausea and vomiting induced by moderately and highly emetogenic chemotherapy (\u963f\u745e\u5339\u5766\u9884\u9632\u4e2d\u9ad8\u5ea6\u81f4\u5410\u6027\u5316\u7597\u65b9\u6848\u6240\u81f4\u6076\u5fc3\u5455\u5410\u7684Meta\u5206\u6790).","volume":"26","author":"Qiu","year":"2017","journal-title":"Chinese J New Drugs"},{"key":"R60-20250524","first-page":"2265","article-title":"Effects of aprepitant triple therapy on safety and life quality of malignant cancer chemotherapy patients: a meta-analysis (\u963f\u745e\u5339\u5766\u4e09\u8054\u7597\u6cd5\u5bf9\u6076\u6027\u80bf\u7624\u5316\u7597\u60a3\u8005\u5b89\u5168\u6027\u53ca\u751f\u6d3b\u8d28\u91cf\u5f71\u54cd\u7684Meta\u5206\u6790).","volume":"29","author":"Huang","year":"2018","journal-title":"China Pharm"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T18:00:38Z","timestamp":1748109638000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":60,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035952","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]}}}